Compounds > carmethizole
Page last updated: 2024-11-08

carmethizole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carmethizole: RN & structure given in first source; RN given refers to HCl; RN for parent cpd not available 2/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164021
CHEMBL ID23804
SCHEMBL ID9274863
MeSH IDM0162229

Synonyms (19)

Synonym
nsc602668
NCI60_004565
carmethizole
nsc371417
nsc-371417
1h-imidazole-4, 1-methyl-2-(methylthio)-, bis(methylcarbamate) (ester)
[1-methyl-5-(methylcarbamoyloxymethyl)-2-methylsulfanyl-imidazol-4-yl]methyl n-methylcarbamate
1h-imidazole-4,5-dimethanol, 1-methyl-2-(methylthio)-, bis(methylcarbamate) (ester), hydrochloride (10:13)
(1-methyl-4-((((methylamino)carbonyl)oxy)methyl)-2-(methylthio)-1h-imidazol-5-yl)methyl methylcarbamate hydrochloride
CHEMBL23804
117120-88-4
[1-methyl-5-(methylcarbamoyloxymethyl)-2-methylsulfanylimidazol-4-yl]methyl n-methylcarbamate
1-methyl-2-(methylthio)-4,5-bis(hydroxymethyl)imidazole-bis(n-methylcarbamate)
1h-imidazole-4,5-dimethanol, 1-methyl-2-(methylthio)-, bis(methylcarbamate) (ester)
SCHEMBL9274863
[1-methyl-4-(([(methylamino)carbonyl]oxy)methyl)-2-(methylsulfanyl)-1h-imidazol-5-yl]methyl methylcarbamate #
BGYXTIDVSRHUEP-UHFFFAOYSA-N ,
1h-imidazole-4,5-dimethanol, 1-methyl-2-methylthio-, bis(methylcarbamate) ester
DTXSID80151706

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (97)

Assay IDTitleYearJournalArticle
AID151406Change in tumor cell population in ip implanted LOX amelanotic melanoma in mice after administration of compound at 25 mg/kg1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID112011Body weight difference (BWD) of test animals administered with 200 mg/kg compound is determined on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120832The toxicity day was evaluated on day 14 for M5076 minus 1 tumor cells of test animals dosed with 100 mg/kg of compound; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116348Ability of 12.5 mg/kg of compound to kill tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID46167Rate constants (1/s x 10e4) for loss of compound when incubated with calf thymus DNA in SHE buffer (pH 7.0) at 37 degree Centigrade, as determined by HPLC1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
DNA-Directed alkylating agents. 7. Synthesis, DNA interaction, and antitumor activity of bis(hydroxymethyl)- and bis(carbamate)-substituted pyrrolizines and imidazoles.
AID120827The toxicity day was evaluated on day 0 for LOX tumor cells of test animals dosed with 25 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID150381Compound was evaluated for reduction in P388 (type I DNA) cell numbers to 50% of control values after a 72 hour exposure.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
DNA-Directed alkylating agents. 7. Synthesis, DNA interaction, and antitumor activity of bis(hydroxymethyl)- and bis(carbamate)-substituted pyrrolizines and imidazoles.
AID120966The toxicity day was evaluated on day 5 for L1210 tumor cells of test animals dosed with 50 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116220Ability of 100 mg/kg of compound to kill M5076 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID151392Percent increase in life span of dying mice tested in vivo at 25 mg/kg against ip implanted P388 Leukemia in mice1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID121209The percent of the median survival time of test mice compared to control mice is % T/C which refers to tumor size in this case. It is determined for mice administered with 100 mg/kg compound on day 11 for MX-1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121348The percent of the median survival time of test mice compared to control mice, administered with 50 mg/kg compound on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116368Ability of 50 mg/kg of compound to kill tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121228The percent of the median survival time of test mice compared to control mice, administered with 100 mg/kg compound on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120964The toxicity day was evaluated on day 5 for L1210 tumor cells of test animals dosed with 200 mg/kg of compound; 0/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120833The toxicity day was evaluated on day 14 for M5076 minus 1 tumor cells of test animals dosed with 200 mg/kg of compound; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121347The percent of the median survival time of test mice compared to control mice, administered with 25 mg/kg compound on on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID100714Percent increase in life span of dying mice tested in vivo at 100 mg/kg against ip implanted LOX amelanotic melanoma in mice (60-day survivors)1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID116370Ability of 6.25 mg/kg of compound to kill tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID151391Percent increase in life span of dying mice tested in vivo at 25 mg/kg against ip implanted LOX amelanotic melanoma in mice (60-day survivors)1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID121211The percent of the median survival time of test mice compared to control mice is % T/C. It is determined for mice administered with 100 mg/kg compound on day 0 for LOX 1 tumor cells.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121349The percent of the median survival time of test mice compared to control mice, administered with 50 mg/kg compound on on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121230The percent of the median survival time of test mice compared to control mice, administered with 12.5 mg/kg compound on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID151399Percent increase in life span of dying mice tested in vivo at 50 mg/kg against ip implanted P388 Leukemia in mice1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID120962The toxicity day was evaluated on day 5 for L1210 tumor cells of test animals dosed with 100 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID8285Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID151421Change in tumor cell population in ip implanted P388 Leukemia in mice after administration of compound at 25 mg/kg1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID116219Ability of 100 mg/kg of compound to kill L1210 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112015Body weight difference (BWD) of test animals administered with 25 mg/kg compound is determined on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121231The percent of the median survival time of test mice compared to control mice, administered with 200 mg/kg compound on on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID106481Concentration required to inhibit tumor growth in MFC7, human breast adenocarcinoma cell line1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID116359Ability of 25 mg/kg of compound to kill tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121212The percent of the median survival time of test mice compared to control mice is % T/C. It is determined for mice administered with 25 mg/kg compound on day 0 for LOX 1 tumor cells.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116355Ability of 25 mg/kg of compound to kill L1210 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID151259Percent increase in life span of dying mice tested in vivo at 100 mg/kg against ip implanted P388 Leukemia in mice1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID111886Body weight difference (BWD) of test animals administered with 12.5 mg/kg compound is determined on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID29309Retention time was determined1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID85750Concentration required to inhibit tumor growth in HT29, human colon adenocarcinoma cell line1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID111881Body weight difference (BWD) of test animals administered with 100 mg/kg compound is determined on day 0 for LOX tumor cells.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120965The toxicity day was evaluated on day 5 for L1210 tumor cells of test animals dosed with 25 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120825The toxicity day was evaluated on day 0 for LOX tumor cells of test animals dosed with 100 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120963The toxicity day was evaluated on day 5 for L1210 tumor cells of test animals dosed with 12.5 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120970Toxicity day evaluation was carried out on day 5 for animal dosed with 100 mg/kg compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID151546Change in tumor cell population in ip implanted P388 Leukemia in mice after administration of compound at 50 mg/kg; toxic1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID120826The toxicity day was evaluated on day 0 for LOX tumor cells of test animals dosed with 200 mg/kg of compound; 3/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120961The toxicity day was evaluated on day 14 for M5076 minus 1 tumor cells of test animals dosed with 50 mg/kg of compound; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121229The percent of the median survival time of test mice compared to control mice, administered with 100 mg/kg compound on on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116350Ability of 200 mg/kg of compound to kill M5076 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID111874Body Weight Difference (BWD) of test animals administered with 6.25 mg/kg compound is determined on day 5 for P388 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112020Body weight difference (BWD) of test animals administered with 60 mg/kg compound is determined on day 1 for MX-1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121227The percent of the median survival time of test mice compared to control mice is determined for mice administered with 12.5 mg/kg compound1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112018Body weight difference (BWD) of test animals administered with 50 mg/kg compound is determined on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120828The toxicity day was evaluated on day 0 for LOX tumor cells of test animals dosed with 50 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120960The toxicity day was evaluated on day 14 for M5076 minus 1 tumor cells of test animals dosed with 400 mg/kg of compound; 1/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID151264Percent increase in life span of dying mice tested in vivo at 12.5 mg/kg against ip implanted P388 Leukemia in mice1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID121224The percent of the median survival time of test mice compared to control mice is determined for mice administered with 50 mg/kg compound1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112017Body weight difference (BWD) of test animals administered with 50 mg/kg compound is determined on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID157053Concentration required to inhibit tumor growth in PSN-1, human pancreatic carcinoma cell line1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID112012Body weight difference (BWD) of test animals administered with 200 mg/kg compound is determined on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID96301Concentration required to inhibit tumor growth in L1210, murine lymphocytic leukemia cell line1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID100870Change in tumor cell population in ip implanted LOX amelanotic melanoma in mice after administration of compound at 200 mg/kg; toxic1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID151413Change in tumor cell population in ip implanted P388 Leukemia in mice after administration of compound at 12.5 mg/kg1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID120992Toxicity day evaluation was carried out on day 5 for animal dosed with 12.5 mg/kg compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID111885Body weight difference (BWD) of test animals administered with 100 mg/kg compound is determined on day 5 for P388 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112014Body weight difference (BWD) of test animals administered with 25 mg/kg compound is determined on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID100854Percent increase in life span of dying mice tested in vivo at 50 mg/kg against ip implanted LOX amelanotic melanoma in mice (60-day survivors)1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID120834The toxicity day was evaluated on day 14 for M5076 minus 1 tumor cells of test animals dosed with 25 mg/kg of compound; 10/101989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120990Toxicity day evaluation was carried out on day 5 for animal dosed with 50 mg/kg compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121213The percent of the median survival time of test mice compared to control mice is % T/C. It is determined for mice administered with 50 mg/kg compound on day 0 for LOX 1 tumor cells.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121226The percent of the median survival time of test mice compared to control mice is determined for mice administered with 6.25 mg/kg compound1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID111869Body Weight Difference (BWD) of test animals administered with 12.5 mg/kg compound is determined on day 5 for P388 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID100722Percent increase in life span of dying mice tested in vivo at 200 mg/kg against ip implanted LOX amelanotic melanoma in mice (60-day survivors)1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID121220The percent of the median survival time of test mice compared to control mice is determined for mice administered with 25 mg/kg compound1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120831The toxicity day was evaluated on day 11 for MX-1 tumor cells of test animals dosed with 60 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112013Body weight difference (BWD) of test animals administered with 25 mg/kg compound is determined on day 0 for LOX tumor cells.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID111882Body weight difference (BWD) of test animals administered with 100 mg/kg compound is determined on day 1 for MX-1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120982Toxicity day evaluation was carried out on day 5 for animal dosed with 25 mg/kg compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112010Body weight difference (BWD) of test animals administered with 200 mg/kg compound is determined on day 0 for LOX tumor cells.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116356Ability of 25 mg/kg of compound to kill M5076 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID111884Body weight difference (BWD) of test animals administered with 100 mg/kg compound is determined on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120830The toxicity day was evaluated on day 11 for MX-1 tumor cells of test animals dosed with 200 mg/kg of compound; 1/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116363Ability of 50 mg/kg of compound to kill L1210 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120829The toxicity day was evaluated on day 11 for MX-1 tumor cells of test animals dosed with 100 mg/kg of compound; 6/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121210The percent of the median survival time of test mice compared to control mice is % T/C which refers to tumor size in this case. It is determined for mice administered with 60 mg/kg compound on day 11 for MX-1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID100977Change in tumor cell population in ip implanted LOX amelanotic melanoma in mice after administration of compound at 50 mg/kg1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID100862Change in tumor cell population in ip implanted LOX amelanotic melanoma in mice after administration of compound at 100 mg/kg1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID112019Body weight difference (BWD) of test animals administered with 50 mg/kg compound is determined on day 5 for P388 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121214The percent of the median survival time of test mice compared to control mice is determined for mice administered with 100 mg/kg compound1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116345Ability of 12.5 mg/kg of compound to kill L1210 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID120991Toxicity day evaluation was carried out on day 5 for animal dosed with 6.25 mg/kg compound; 5/61989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116364Ability of 50 mg/kg of compound to kill M5076 tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID112016Body weight difference (BWD) of test animals administered with 50 mg/kg compound is determined on day 0 for LOX tumor cells.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID116223Ability of 100 mg/kg of compound to kill tumor cells in mice is expressed as the log of the tumor cell population at the onset of treatment minus the log of the tumor cell population at the end of treatment1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID111871Body Weight Difference (BWD) of test animals administered with 25 mg/kg compound is determined on day 5 for P388 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID121232The percent of the median survival time of test mice compared to control mice, administered with 25 mg/kg compound on day 5 for L1210 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
AID151408Change in tumor cell population in ip implanted P388 Leukemia in mice after administration of compound at 100 mg/kg; toxic1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
AID111883Body weight difference (BWD) of test animals administered with 100 mg/kg compound is determined on day 14 for M5076 minus 1 tumor cells1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's5 (71.43)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.61 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		1.9710amino-acid anion
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		1.9710N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
cb 10375
trimelamol: structure given in first source		1.9810
pancratistatin
pancratistatin: an isocarbostyril from Amaryllidaceae		1.9810citraconoyl group
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		1.9710L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
rhizoxin
rhizoxin: from Rhizopus chinensis; causal agent of rice seedling blight; structure given in first source. rhizoxin : An macrolide antibiotic isolated from the pathogenic plant fungus Rhizopus microsporus. It also exhibits antitumour and antimitotic activity.		1.98101,3-oxazoles;
epoxide;
macrolide antibiotic		antimitotic;
antineoplastic agent;
metabolite
nsc 262266
NSC 262266: structure given in first source		1.9810
bryostatin 1
bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S*-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Leukemia
[description not available]		01.9710
B16 Melanoma
[description not available]		02.6730
Experimental Mammary Neoplasms
[description not available]		02.3820
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.940
Carcinoma, Oat Cell
[description not available]		01.9810
Leukemia L 1210
[description not available]		02.3820
Cancer of Lung
[description not available]		01.9810
Experimental Neoplasms
[description not available]		01.9810
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9810
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		01.9810